Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,994 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial.
Lee DW, Jung KH, Lee KH, Park YH, Lee KS, Sohn J, Ahn HK, Jeong JH, Koh SJ, Kim JH, Kim HJ, Lee KE, Kim HJ, Yang YW, Park KH, Lee J, Won HS, Kim TY, Im SA. Lee DW, et al. Among authors: kim hj, kim ty, kim jh. Eur J Cancer. 2024 Jan;197:113456. doi: 10.1016/j.ejca.2023.113456. Epub 2023 Nov 20. Eur J Cancer. 2024. PMID: 38104354 Clinical Trial.
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
Park IH, Im SA, Jung KH, Sohn JH, Park YH, Lee KS, Sim SH, Park KH, Kim JH, Nam BH, Kim HJ, Kim TY, Lee KH, Kim SB, Ahn JH, Lee S, Ro J. Park IH, et al. Among authors: kim sb, kim hj, kim ty, kim jh. Cancer Res Treat. 2019 Jan;51(1):43-52. doi: 10.4143/crt.2017.562. Epub 2018 Feb 14. Cancer Res Treat. 2019. PMID: 29458237 Free PMC article. Clinical Trial.
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH, Kim TY, Kim GM, Kang SY, Park IH, Kim JH, Lee KE, Ahn HK, Lee MH, Kim HJ, Kim HJ, Lee JI, Koh SJ, Kim JY, Lee KH, Sohn J, Kim SB, Ahn JS, Im YH, Jung KH, Im SA; Korean Cancer Study Group (KCSG). Park YH, et al. Among authors: kim jy, kim sb, kim hj, kim ty, kim gm, kim jh. Lancet Oncol. 2019 Dec;20(12):1750-1759. doi: 10.1016/S1470-2045(19)30565-0. Epub 2019 Oct 24. Lancet Oncol. 2019. PMID: 31668850 Clinical Trial.
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16).
Sim SH, Park IH, Jung KH, Kim SB, Ahn JH, Lee KH, Im SA, Im YH, Park YH, Sohn J, Kim YJ, Lee S, Kim HJ, Chae YS, Park KH, Nam BH, Lee KS, Ro J. Sim SH, et al. Among authors: kim sb, kim yj, kim hj. Br J Cancer. 2019 Dec;121(12):985-990. doi: 10.1038/s41416-019-0618-z. Epub 2019 Nov 6. Br J Cancer. 2019. PMID: 31690831 Free PMC article. Clinical Trial.
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10).
Lee S, Im SA, Kim GM, Jung KH, Kang SY, Park IH, Kim JH, Lee KE, Ahn HK, Lee MH, Kim HJ, Kim HJ, Lee JI, Koh SJ, Park YH. Lee S, et al. Among authors: kim hj, kim gm, kim jh. Cancers (Basel). 2020 Nov 5;12(11):3265. doi: 10.3390/cancers12113265. Cancers (Basel). 2020. PMID: 33167305 Free PMC article.
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16).
Kim SH, Im SA, Suh KJ, Lee KH, Kim MH, Sohn J, Park YH, Kim JY, Jeong JH, Lee KE, Choi IS, Park KH, Kim HJ, Cho EK, Park SY, Kim M, Kim JH. Kim SH, et al. Among authors: kim jy, kim hj, kim m, kim mh, kim jh. Eur J Cancer. 2023 Dec;195:113386. doi: 10.1016/j.ejca.2023.113386. Epub 2023 Oct 14. Eur J Cancer. 2023. PMID: 37890351 Free article. Clinical Trial.
A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
Lee KH, Kim JY, Lee MH, Han HS, Lim JH, Park KU, Park IH, Cho EK, Yoon SY, Kim JH, Choi IS, Park JH, Choi YJ, Kim HJ, Jung KH, Kim SY, Oh DY, Im SA. Lee KH, et al. Among authors: kim jy, kim hj, kim sy, kim jh. Support Care Cancer. 2016 Apr;24(4):1709-17. doi: 10.1007/s00520-015-2963-7. Epub 2015 Oct 1. Support Care Cancer. 2016. PMID: 26423618 Free PMC article. Clinical Trial.
Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis.
Park JH, Im SA, Byun JM, Kim KH, Kim JS, Choi IS, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY. Park JH, et al. Among authors: kim hj, kim ty, kim js, kim kh. J Breast Cancer. 2017 Dec;20(4):347-355. doi: 10.4048/jbc.2017.20.4.347. Epub 2017 Dec 19. J Breast Cancer. 2017. PMID: 29285039 Free PMC article.
Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
Park I, Kim BS, Lim HY, Kim HJ, Lee HJ, Choi YJ, Park KH, Lee KH, Yoon S, Hong B, Hong JH, Ahn H, Lee JL. Park I, et al. Among authors: kim bs, kim hj. Eur J Cancer. 2020 Mar;127:183-190. doi: 10.1016/j.ejca.2019.08.034. Epub 2019 Oct 24. Eur J Cancer. 2020. PMID: 31668839 Clinical Trial.
20,994 results
You have reached the last available page of results. Please see the User Guide for more information.